Tryp Therapeutics is a clinical stage drug development company led by a management team with extensive drug development experience that is advancing transformative medicines with existing clinical data and known safety profiles for diseases with no effective first-line treatments. The company is building a diversified portfolio of product candidates targeting neuropsychiatric and oncology indications with high unmet medical needs.
James Kuo, Chief Executive Officer
William Garner, Executive Chairman
Jay R. Campbell, Chief Business Officer
TRP-8802 | Prader-Willi Syndrome (PWS)
Serious and complex genetic disorder estimated to affect 8,000-11,000 patients in the U.S. and Europe and market size of ~US$800m according to Jefferies Equity Research.
TRP-8803 | Fibromyalgia
Chronic and debilitating CNS/neurobiological disorder. The fibromyalgia treatment market is estimated to surpass US$3.6B by 2026.
TRP-1001 | Sarcomas
Oncology is the leading therapeutic category and represented 25% of all drug sales in 2018, which equated to ~US$151B in 2018.